Eltrombopag tablet - Revolade | Apple pharmaceuticals

Eltrombopag 

DESCRIPTION

Eltrombopag is a prescription drug which is used under the guidance of the doctor.
Eltrombopag drug may be used as part of combination therapy. Thereby drug may need to take it with other medications.

INDICATION

Eltrombopag is mainly indicated for the treatment of patients having :

• Reduced platelet levels due to chronic immune thrombocytopenia
• Reduced platelet counts due to chronic hepatitis C virus infection

Severe Aplastic Anemia :

• First line treatment of severe Aplastic Anemia
• Treatment of refractory severe Aplastic Anemia

MECHANISM OF ACTION

Eltrombopag be part of the class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions. Eltrombopag works by raise cells in bone marrow and leads these cells to make various platelets. This effect reduces the risk of bleeding.

SIDE EFFECTS  

Common side effects:

• low red blood cells
• nausea
• fever
• weakness
• pain in head
• cough
• decreased appetite
• flu
• diarrhoea.

Serious side effects:

• Urine in dark color
• Yellowing of your skin
• Abdomen swelling
• Confusion
• Chest pain
• Dyspnea
• Cloudy vision
• Sensitivity to light
• Seeing circles around lights
• Swelling of legs.

PRECAUTION

The drug causes warning condition, call the doctor while new medication interaction Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death.

DRUG INTERACTION

Eltrombopag interaction with these drugs ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads an increase of side effects. hence the doctor may reduce your dosage of these drugs if required.

PREGNANCY 

Pregnancy category is C
Use the Eltrombopag with caution if asset outweighs risks. Animal studies reveal risk and human studies not available or neither animal nor human studies done.

LACTATION

The presence of Eltrombopag or metabolites in human milk, the drug has possible serious side effects for the breastfed child. The drug is not recommended during breastfeeding

STORAGE CONDITION

Store at room temperature 20° and 25°.
Discard the left-out medicine if not used within 30 minutes.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

Eltrombopag

Evertor 10mg online | Apple Pharmaceuticals

Indication of Evertor

Primarily Evertor tablets indicated for the treatment :

1. kidney carcinoma
2. Breast carcinoma
3. Brain carcinoma

Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Dosage regimen of Evertor

In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
 The prescribed dosage is 10mg should be taken as a single dose.

 In Brain or intracranial cancer: 
 The prescribed dosage of Evertor as a single dose. is 4.5mg/m2 given orally.

 In pediatric: 
 The pediatric dosage of Evertor as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

 Mechanism

 Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, Finally causes cell growth arrest and apoptosis.

 Side Effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

 Drug-Drug interaction

Evertor interaction with a strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Interaction of Evertor with strong CYP3A4 inducers will be increasing the disclosure of Everolimus. Combination of Evertor with cyclosporine will increase the AUC level of Everolimus frequently.

Contraindication

If patients are contraindicated to the components present in the Evertor tablets. Some anaphylactic reaction occurs.

Pregnancy and lactation

Pregnancy category of Everolimus In patients Evertor is used only after knowing the benefits to the mother exceed the risk to the fetus. Breastfeeding should not be suggested.

Storage and handling

Evertor tablet store at 25°C Store the medicine away from moisture, heat, and light.

Overdosage

The over dosage of Everolimus is limited If overdosage occurs patient must be provided with supportive measures. And monitor evidence of toxicity in Everolimus overdosage.

Missed Dose

In case of the missed dose, patients must consult with a medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

Evertor Tablets

Everolimus Tablet | Apple Pharmaceuticals

Description

Everolimus belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everolimus is an immunosuppressive macrolide.

Indication

Primarily Everolimus tablets indicated for the treatment : 

kidney carcinoma, Breast carcinoma, Brain carcinoma.

Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Dosage Regimen

In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.

In Brain or intracranial cancer:
The prescribed dosage of Everolimus as a single dose. is 4.5mg/m2 given orally 

In pediatric:
The pediatric dosage of Everolimus as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Drug Profile

Everolimus consist of an active ingredient known as Everolimus which is intruded with the of cancer cell and a process is slowing down. Everolimus tablets is not a curable medication, which helps to slow their spreading into the body.

Mechanism

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.

Side Effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

Drug-Drug interaction

Everolimus interaction with a strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Interaction of Everolimus with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.

Combination of Everolimus with cyclosporine will be increasing the AUC level of Everolimus frequently. Combination ketoconazole with Everolimus tablet or other CYP3A4 inhibitors will be increasing the plasma concentration and AUC of Everolimus.

Pregnancy and lactation

Pregnancy category of Everolimus In patients Everolimus is used only after knowing the benefits to the mother exceed the risk to the s. Breastfeeding should not be suggested

Storage and handling

Everolimus tablet store at 25°C Store the medicine away from moisture, heat, and light.

Missed Dose

In case of a missed dose, patients must consult with a medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

Everolimus Tablets

BORTEZOMIB-INJECTION (Velcade) side effects,Dosage & Uses, and drug interactions| Apple Pharmaceuticals.

Description

Bortezomib belongs to a class of anti-cancer medicine, which is in the form of lyophilized powder A first beneficial proteasome inhibitor is known as Bortezomib proteasome is a cellular structure which breaks the proteins.

Important points

Bortezomib should be used alone or combined with dexamethasone Three-week course is considered as therapy cycle A minimum 72 hours should slip away between constant doses of Bortezomib.

Key points

Partially, 72 hours should be passing between following doses of Bortezomib. 

Dosage & Administration

Bortezomib (lyophilized powder form) is reconstituted by using 0.9% sodium chloride (NS) Bortezomib should be reconstituted in 3.5ml NS The route of administration is IV bolus Intrathecal not use for administration.

In adults:

Mantle cell lymphoma

The Bortezomib recommended dose for untreated mantle cell lymphoma is; 1.3mg/m2 of Bortezomib administered as IV bolus given as two times weekly by combining with rituximab, cyclophosphamide, doxorubicin, and tablet prednisolone for two weeks (day I, IV, VIII & XI) followed rest period of 10 days (day II through 21).

In Relapse stage

The usual dose of Bortezomib is 1.3mg/m2 should be administered through IV bolus or subcutaneous as two times for two weeks (day1, 4, 8, and 11) followed by a ten day rest course (day 12 through 21) Treatment schedule increased above 8 cycles may be taken once weekly for 4 weeks (day 1, 8, 15, and 22), followed by 13 day rest (day 23 over 35)

Mechanism of action : 

Pharmacological category: anti-neoplastic agent or proteasome inhibitor Bortezomib is a type of chymotrypsin-like activity unpredictable inhibitor of the 26S proteasome in human cells. The 26S proteasome is a big protein multiplex which degraded the accompany proteins The functioning site of proteasome has Chymotrypsin like Trypsin like Postglutamyl peptide hydrolysis activity The 26S proteasome enzyme recede assorted proteins which demanding to tumor cells survival like cyclins, tumor suppressors, BCL-2 & cyclin-dependent kinase inhibitors Prevention of these degenerations, sensitizes cells to apoptosis and cell arrest.

Side effects

Black tarry stools, Bleeding gums, Blood in urine, Blurred vision, Body aches, Burning, crawling, itching, numbness, prickling, Chest pain.

Storage

Bortezomib vial should be stored at 20°C to 25°C (68°F to 77°F) excursion between 15°C to 30°C (59°F to 86°F) Keep away from light and heat.

Missed Dose

If the patient fails to take the dose of Bortezomib, must consult with a medical oncologist and followed the dosing schedules. Do not self-administered.

FOR MORE INFORMATION:

EMAIL:

 applepharmaceutical@gmail.com

PHONE:

+91- 9987711567

VISIT US:

Bortezomib Injection